Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Breast Cancer Surgery Clear all
Completed Phase 2 Interventional Results available

Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.

NCT00921115
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
Fulvestrant, Anastrazole
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 18, 2023 · Synced Jul 22, 2026, 10:22 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Axillary Lymph Node Preservation Surgery in Reducing Lymphedema in Patients With Breast Cancer

NCT00932035
View directory record Official record
Conditions
Breast Cancer
Interventions
axillary lymph node dissection, isosulfan blue based lymphatic mapping, quality-of-life assessment, Questionnaire administration
Procedure · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Duarte, California • Sacramento, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 6, 2017 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Optical Spectroscopy During Breast Cancer Surgery and Core Needle Biopsy

NCT00734838
View directory record Official record
Conditions
Breast Cancer
Interventions
High Resolution Microendoscope
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Jul 22, 2026, 10:22 AM EDT
Withdrawn No phase listed Observational

Effects of Bariatric Surgery on Breast Density Improvement and Impact on Breast Cancer Risk in Severe Obese Patients

NCT04170335
View directory record Official record
Conditions
Breast Cancer, Morbid Obesity, Bariatric Surgery Candidate
Interventions
Bariatric surgery
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
40 Years to 74 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Jul 22, 2026, 10:22 AM EDT
Completed No phase listed Observational

Electronic Medical Record-Based Nudge to Reduce SLNB

NCT06006910
View directory record Official record
Conditions
Breast Cancer, Estrogen-receptor-positive Breast Cancer
Interventions
Column-based nudge in the EHR, No column-based nudge in the EHR
Behavioral
Lead sponsor
University of Pittsburgh Medical Center
Other
Eligibility
70 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 13, 2024 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Phase 3 Interventional

The Treatment of Stage I and II Carcinoma of the Breast With Mastectomy and Axillary Dissection Versus Excisional Biopsy, Axillary Dissection, and Definitive Irradiation

NCT01468883
View directory record Official record
Conditions
Breast Cancer
Interventions
M, X
Procedure · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1979 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Not applicable Interventional

The Effect of Meditation and Massage Therapy for Breast Cancer Patients Undergoing Tissue Reconstruction

NCT01736605
View directory record Official record
Conditions
Breast Cancer
Interventions
Massage, Massage combined with meditation
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Jul 22, 2026, 10:22 AM EDT
Recruiting Not applicable Interventional

A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery

NCT06127979
View directory record Official record
Conditions
Breast Cancer
Interventions
core needle biopsy, blood draw
Procedure · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Jul 22, 2026, 10:22 AM EDT
Recruiting No phase listed Observational

Long-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer

NCT06888388
View directory record Official record
Conditions
Breast Cancer Surgery
Interventions
Nipple Sparing Mastectomy (NSM), Skin-Sparing Mastectomy (SSM), Total (Simple) Mastectomy
Procedure
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
4,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
4
States / cities
New Haven, Connecticut • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Jul 22, 2026, 10:22 AM EDT
Not listed Not applicable Interventional

Intraoperative Use of ClearEdge Device in Breast Conserving Surgery

NCT05456373
View directory record Official record
Conditions
Breast Cancer
Interventions
ClearEdge device
Device
Lead sponsor
LS BioPath
Industry
Eligibility
18 Years and older · Female only
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Phase 3 Interventional Results available

Investigation of Novel Surgical Imaging for Tumor Excision

NCT03686215
View directory record Official record
Conditions
Breast Cancer
Interventions
Study Device Arm
Combination Product
Lead sponsor
Lumicell, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
406 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Mobile, Alabama • Scottsdale, Arizona • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Jul 22, 2026, 10:22 AM EDT
Terminated Phase 2 Interventional

Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer

NCT03979508
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Breast Fibrocystic Change, Breast Lobular Carcinoma In Situ, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Abemaciclib, Therapeutic Conventional Surgery
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Jul 22, 2026, 10:22 AM EDT
Completed No phase listed Observational

Correlation of Menstrual Cycle Phase at Time of Primary Surgery With 5-Year Disease-Free Survival in Women With Stage I or Stage II Breast Cancer

NCT00002762
View directory record Official record
Conditions
Breast Cancer, Perioperative/Postoperative Complications
Interventions
patient interviewing to obtain menstrual history, blood sampling
Behavioral · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
1,118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2009
U.S. locations
52
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Jul 22, 2026, 10:22 AM EDT
Recruiting Phase 2 Interventional

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

NCT06797635
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer
Interventions
Patritumab deruxtecan, Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin hydrochloride, Epirubicin hydrochloride, Cyclophosphamide, Capecitabine, Olaparib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
8
States / cities
Santa Monica, California • Skokie, Illinois • Billings, Montana + 5 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 22, 2026, 10:22 AM EDT
Terminated Phase 1 Interventional

Contrast Enhanced Ultrasound and Shear Wave Elastography in Measuring Response in Patients With Breast Cancer Receiving Chemotherapy Before Surgery

NCT02067884
View directory record Official record
Conditions
Breast Cancer
Interventions
dynamic contrast-enhanced ultrasound imaging, shear wave elastography, Definity, (Lipid Microspheres) Intravenous Suspension, Philips Shear Wave Elastography
Procedure · Drug · Device
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Phase 2 Interventional

Combination Chemotherapy in Treating Women With Breast Cancer That is Metastatic or Cannot be Treated With Surgery

NCT00015886
View directory record Official record
Conditions
Breast Cancer
Interventions
docetaxel, fluorouracil
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
6
States / cities
Goldsboro, North Carolina • Greenville, North Carolina • Winston-Salem, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2018 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer

NCT00052351
View directory record Official record
Conditions
Breast Cancer
Interventions
recombinant fowlpox-CEA(6D)/TRICOM vaccine, recombinant vaccinia-CEA(6D)-TRICOM vaccine, sargramostim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Jul 22, 2026, 10:22 AM EDT
Completed No phase listed Observational

Implementation of a Web-based Decision Aid for Breast Cancer Surgery

NCT03304002
View directory record Official record
Conditions
Breast Cancer, Surgery
Interventions
Breast Cancer Surgery Decision Aid
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 100 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Memphis, Tennessee • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer

NCT00068341
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, carboplatin, docetaxel
Biological · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
4
States / cities
Little Rock, Arkansas • Los Angeles, California • Pomona, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2020 · Synced Jul 22, 2026, 10:22 AM EDT
Completed No phase listed Observational

Supportive Care Questionnaires in Gathering Data on Unmet Needs and Health-Related Quality of Life in Latina Breast Cancer Survivors After Surgery, Chemotherapy, or Radiation Therapy

NCT02545023
View directory record Official record
Conditions
Breast Carcinoma, Cancer Survivor
Interventions
Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Jul 22, 2026, 10:22 AM EDT
Not listed Phase 2 Interventional

Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.

NCT00777673
View directory record Official record
Conditions
Breast Cancer
Interventions
Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim
Drug
Lead sponsor
University of Tennessee Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Memphis, Tennessee • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 3, 2013 · Synced Jul 22, 2026, 10:22 AM EDT
Active, not recruiting Phase 1 Interventional

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

NCT01366144
View directory record Official record
Conditions
Breast Carcinoma, Carcinoma of Unknown Primary, Endometrial Carcinoma, Esophageal Carcinoma, Liver Failure, Lung Carcinoma, Malignant Head and Neck Neoplasm, Malignant Testicular Neoplasm, Melanoma, Metastatic Malignant Solid Neoplasm, Ovarian Carcinoma, Renal Failure, Unresectable Malignant Neoplasm, Urothelial Carcinoma
Interventions
Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Pharmacological Study, Veliparib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
17
States / cities
Duarte, California • Sacramento, California • South Pasadena, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 22, 2026, 10:22 AM EDT
Completed Phase 2 Interventional Results available

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

NCT02530489
View directory record Official record
Conditions
Breast Adenocarcinoma, Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma
Interventions
Atezolizumab, Nab-paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Jul 22, 2026, 10:22 AM EDT
Terminated Not applicable Interventional Results available

Metformin Hydrochloride in Treating Women With Stage I or Stage II Breast Cancer That Can Be Removed By Surgery

NCT00984490
View directory record Official record
Conditions
Breast Cancer
Interventions
metformin hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Atlanta, Georgia • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Jul 22, 2026, 10:22 AM EDT